In‐flight glycaemic control using automated insulin delivery systems: A within‐subject comparative pilot study
Authors' conclusion
AID systems maintained robust glycaemic control and safety during commercial flights, comparable to ground-based conditions. These data support the feasibility of in-flight AIDs use and provide a basis for future regulatory and clinical practice updates. Larger, multicenter studies are needed to generalize findings.
Study context
- Population
- Adults with T1D using commercial AID (MiniMed780G; Omnipod 5; Control-IQ; CamAPS FX with YpsoPump, n = 5 per system); age 37.9 ± 12.8 years, HbA1c 52.3 ± 4.9 mmol/mol, time in range (TIR) 74 ± 9.8%, diabetes duration 19.25 ± 10.6 years5 per AID system
- Participants
- 20 adults
- Comparison
- AID use in-flight vs on-ground
- In-flightn = 20
- On-groundn = 20reference
- Outcome
- TIR (3.9-10.0 mmol/L)
Methodological detailswithin-subject comparison, mid-haul commercial flights vs matched ground-based conditions
- Within-subject comparison
- Mid-haul commercial flights vs matched ground-based conditions
Main finding
As reported in the abstract
Mean difference
4.6 %
95% CI −5.0- 14.2
By group
Between In-flight and On-ground
mean difference 4.6 % (95% CI −5.0- 14.2)
Further findings
TITR (3.9-7.8 mmol/L)
TAR
TBR
Insulin delivery
Bolus insulin dosing
Insulin delivery
- Insulin delivery slightly increased in-flight, driven by bolus dosing
Safety
- Episodes of level 2 hypoglycaemia, DKA or device failure
- 0
Original publication
In‐flight glycaemic control using automated insulin delivery systems: A within‐subject comparative pilot study. Diabetes Obes Metab. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →